Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Zdravka Medarova
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Transcode Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Medarova has a financial interest in Transcode Therapeutics, a privately held company focused on the discovery, development, and commercialization of a pipeline of microRNA therapeutics for treating metastatic cancer, initially metastatic breast cancer. Transcode Therapeutics’ IP is based on data and technology that were generated from this study involving animal models for eradicating metastatic tumor cells while sparing healthy organs and having no systemic toxicity compared to chemotherapy; thusly, the company could have an interest in the IP that could result from this study.
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer
A major focus of the breast cancer research and clinical community is on developing methods to effectively interfere with the disease after it has spread from the primary site. In the proposed research, we will utilize an imaging-capable nanodrug, which distributes to tumors and the lymphatics in vivo. The nanodrug will carry gene therapy, uniquely targeting the metastatic capabilities of tumor cells, through inhibiting specific small no-coding RNA molecules. We hope to be able to visualize the distribution of therapy in vivo by MRI and optical imaging and to successfully prevent and/or reverse the formation of metastases.
Filed on March 07, 2016.
Tell us what you know about Zdravka Medarova's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Zdravka Medarova filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
| Zdravka Medarova | Massachusetts General Hospital | Conflict of Interest | Transcode Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.